Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the...
Learn moreInternational Women’s Day and Parkinson’s
On 8 March, we celebrate International Women’s Day by shining a light on the work of female researchers and scientists who have made significant contributions to the Parkinson’s community, and the impact of their work in advancing our understanding of the role of sex and…
Cure Parkinson’s Fundraising Heroes: February 2024
February’s fundraising heroes have all taken on long term fundraising events to support our research. An untraditional triathlon Fundraising heroes Phil and Sue created their own triathlon-inspired challenge to raise funds for our research following Phil’s Parkinson’s diagnosis and to mark Sue’s 70th birthday. They…
Latest updates in the field of neurotrophic factors in Parkinson’s
Neurotrophic factors such as GDNF are still being actively investigated as a potential treatment for Parkinson’s, and alternative methods of delivery are currently being explored.
Cure Parkinson’s Fundraising Heroes: January 2024
It’s a great time of year to start thinking about trying something new, so get inspired by some of our 2023 fundraising heroes who came up with some brilliant and inventive ways to raise funds and awareness for our research. Community Fêtes In June, keen…
Cure Parkinson’s welcomes Rory Cellan-Jones as new patron
Cure Parkinson’s is delighted to announce that Rory Cellan-Jones, former technology correspondent for the BBC, writer, ‘Movers & Shakers’ podcaster, technology advisor and owner of one the UK’s most beloved rescue dogs, has joined Cure Parkinson’s as a patron. Rory was diagnosed with Parkinson’s in…